The study met its primary endpoint, with no procedure or device related serious adverse events reported from implant through seven days post-removal of the CBGM sensor lead. Glucotrack (NASDAQ ...

(RTTNews) - Glucotrack, Inc. (GCTK), a medical technology ... This milestone study, which aimed to evaluate the safety of the implant, use, and removal of the CBGM sensor lead, confirms the ...

Glucotrack calls its device, which has no external on-body component, a continuous blood glucose monitor (CBGM). The implant is around the length and thickness of three US nickels, with a total ...

Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technologyRUTHERFORD, N.J., Feb. 26, 2025 (GLOBE ...

Glucotrack, Inc. GCTK reports it has achieved a significant milestone in its mission to transform diabetes management through three distinct advances: direct blood glucose measurement, hassle-free ...

Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...

Glucotrack (GCTK) announced that Ted Williams has been named Vice President of Regulatory Affairs, effective immediately. He served as Vice President, Regulatory Affairs/Quality Assurance for ...

Goode, PhD, President & Chief Executive Officer of Glucotrack.“With these positive ... related serious adverse events reported from implant through seven days post-removal of the CBGM sensor ...

Goode, PhD, President & Chief Executive Officer of Glucotrack. "With these positive ... device related serious adverse events reported from implant through seven days post-removal of the CBGM ...